Benitec Biopharma Inc. announced positive interim clinical results from the ongoing BB-301 Phase 1b/2a first-in-human study (NCT06185673) for Patients treated with high dose BB-301 and continued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results